https://www.tradingview.com/symbols/NYSE-TAK/ shows long-term decline since 2008. This is another case study of long-term decline, comparable to LFC and IMBBY
- 🙂 4% CDY. Increased through 2020. https://www.nasdaq.com/market-activity/stocks/tak/dividend-history
- https://money.usnews.com/investing/dividends/slideshows/best-pharmaceutical-stocks-to-buy-for-income?slide=9
- 60B. based in Japan, biggest pharma in Asia.. good diversification
- 🙂 analysts positive.. target price mid Apr $23